Tailored therapy for severe asthma

Francesco Menzella, Mirco Lusuardi, Carla Galeone, Luigi Zucchi

Research output: Contribution to journalArticle

Abstract

Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. A better understanding of pathogenetic mechanisms, phenotypes, endotypes and the new technologies available in the fields of molecular biology and immunogenetics have made it possible to synthesize specific monoclonal antibodies virtually able to interact with any target antigen, or to open a way for new therapeutic target options. At the moment, the only biologic drug available in clinical practice is omalizumab. To overcome the limits of omalizumab, the research has focused on new monoclonal antibodies presenting higher avidity for IgE (e.g. ligelizumab and lumiximab) and ability to interact also with low affinity IgE receptor (FceRII). At present, many new biological drugs with different mechanisms of action and targets are matter of research. It is very important to identify the asthmatic phenotype in order to select the most appropriate drug for the individual patient. The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab). Other interesting drugs have as a target TNF-ci or its soluble receptor (infliximab, golimumab and etanercept) or IL-1 (canakinumab), a cytokine with an important systemic proinflammatory action. Finally, the discovery of increased levels of C5a in the airways of asthmatic patients has led to the synthesis of a specific monoclonal antibody (eculizumab). Further help should come from the identification of biomarkers that can guide in choosing the best treatment for the individual patient, such as IgE for omalizumab or periostin for lebrikizumab.

Original languageEnglish
Article number1
JournalMultidisciplinary Respiratory Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Asthma
Monoclonal Antibodies
Pharmaceutical Preparations
Immunoglobulin E
Cytokines
Phenotype
Therapeutics
IgE Receptors
Immunogenetics
Interleukin-13
Interleukin-5
Interleukin-1
Research
Chronic Obstructive Pulmonary Disease
Interleukin-2
Molecular Biology
Biomarkers
Technology
Antigens
Omalizumab

Keywords

  • Asthma
  • COPD
  • Cytokines
  • Inflammation
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Menzella, F., Lusuardi, M., Galeone, C., & Zucchi, L. (2015). Tailored therapy for severe asthma. Multidisciplinary Respiratory Medicine, 10(1), [1]. https://doi.org/10.1186/2049-6958-10-1

Tailored therapy for severe asthma. / Menzella, Francesco; Lusuardi, Mirco; Galeone, Carla; Zucchi, Luigi.

In: Multidisciplinary Respiratory Medicine, Vol. 10, No. 1, 1, 2015.

Research output: Contribution to journalArticle

Menzella, F, Lusuardi, M, Galeone, C & Zucchi, L 2015, 'Tailored therapy for severe asthma', Multidisciplinary Respiratory Medicine, vol. 10, no. 1, 1. https://doi.org/10.1186/2049-6958-10-1
Menzella, Francesco ; Lusuardi, Mirco ; Galeone, Carla ; Zucchi, Luigi. / Tailored therapy for severe asthma. In: Multidisciplinary Respiratory Medicine. 2015 ; Vol. 10, No. 1.
@article{d7605b73f2b3447f8f04060c213aab03,
title = "Tailored therapy for severe asthma",
abstract = "Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. A better understanding of pathogenetic mechanisms, phenotypes, endotypes and the new technologies available in the fields of molecular biology and immunogenetics have made it possible to synthesize specific monoclonal antibodies virtually able to interact with any target antigen, or to open a way for new therapeutic target options. At the moment, the only biologic drug available in clinical practice is omalizumab. To overcome the limits of omalizumab, the research has focused on new monoclonal antibodies presenting higher avidity for IgE (e.g. ligelizumab and lumiximab) and ability to interact also with low affinity IgE receptor (FceRII). At present, many new biological drugs with different mechanisms of action and targets are matter of research. It is very important to identify the asthmatic phenotype in order to select the most appropriate drug for the individual patient. The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab). Other interesting drugs have as a target TNF-ci or its soluble receptor (infliximab, golimumab and etanercept) or IL-1 (canakinumab), a cytokine with an important systemic proinflammatory action. Finally, the discovery of increased levels of C5a in the airways of asthmatic patients has led to the synthesis of a specific monoclonal antibody (eculizumab). Further help should come from the identification of biomarkers that can guide in choosing the best treatment for the individual patient, such as IgE for omalizumab or periostin for lebrikizumab.",
keywords = "Asthma, COPD, Cytokines, Inflammation, Monoclonal antibodies",
author = "Francesco Menzella and Mirco Lusuardi and Carla Galeone and Luigi Zucchi",
year = "2015",
doi = "10.1186/2049-6958-10-1",
language = "English",
volume = "10",
journal = "Multidisciplinary Respiratory Medicine",
issn = "1828-695X",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Tailored therapy for severe asthma

AU - Menzella, Francesco

AU - Lusuardi, Mirco

AU - Galeone, Carla

AU - Zucchi, Luigi

PY - 2015

Y1 - 2015

N2 - Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. A better understanding of pathogenetic mechanisms, phenotypes, endotypes and the new technologies available in the fields of molecular biology and immunogenetics have made it possible to synthesize specific monoclonal antibodies virtually able to interact with any target antigen, or to open a way for new therapeutic target options. At the moment, the only biologic drug available in clinical practice is omalizumab. To overcome the limits of omalizumab, the research has focused on new monoclonal antibodies presenting higher avidity for IgE (e.g. ligelizumab and lumiximab) and ability to interact also with low affinity IgE receptor (FceRII). At present, many new biological drugs with different mechanisms of action and targets are matter of research. It is very important to identify the asthmatic phenotype in order to select the most appropriate drug for the individual patient. The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab). Other interesting drugs have as a target TNF-ci or its soluble receptor (infliximab, golimumab and etanercept) or IL-1 (canakinumab), a cytokine with an important systemic proinflammatory action. Finally, the discovery of increased levels of C5a in the airways of asthmatic patients has led to the synthesis of a specific monoclonal antibody (eculizumab). Further help should come from the identification of biomarkers that can guide in choosing the best treatment for the individual patient, such as IgE for omalizumab or periostin for lebrikizumab.

AB - Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. A better understanding of pathogenetic mechanisms, phenotypes, endotypes and the new technologies available in the fields of molecular biology and immunogenetics have made it possible to synthesize specific monoclonal antibodies virtually able to interact with any target antigen, or to open a way for new therapeutic target options. At the moment, the only biologic drug available in clinical practice is omalizumab. To overcome the limits of omalizumab, the research has focused on new monoclonal antibodies presenting higher avidity for IgE (e.g. ligelizumab and lumiximab) and ability to interact also with low affinity IgE receptor (FceRII). At present, many new biological drugs with different mechanisms of action and targets are matter of research. It is very important to identify the asthmatic phenotype in order to select the most appropriate drug for the individual patient. The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab). Other interesting drugs have as a target TNF-ci or its soluble receptor (infliximab, golimumab and etanercept) or IL-1 (canakinumab), a cytokine with an important systemic proinflammatory action. Finally, the discovery of increased levels of C5a in the airways of asthmatic patients has led to the synthesis of a specific monoclonal antibody (eculizumab). Further help should come from the identification of biomarkers that can guide in choosing the best treatment for the individual patient, such as IgE for omalizumab or periostin for lebrikizumab.

KW - Asthma

KW - COPD

KW - Cytokines

KW - Inflammation

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84938060732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938060732&partnerID=8YFLogxK

U2 - 10.1186/2049-6958-10-1

DO - 10.1186/2049-6958-10-1

M3 - Article

AN - SCOPUS:84938060732

VL - 10

JO - Multidisciplinary Respiratory Medicine

JF - Multidisciplinary Respiratory Medicine

SN - 1828-695X

IS - 1

M1 - 1

ER -